CA2461248C - Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a - Google Patents

Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a Download PDF

Info

Publication number
CA2461248C
CA2461248C CA 2461248 CA2461248A CA2461248C CA 2461248 C CA2461248 C CA 2461248C CA 2461248 CA2461248 CA 2461248 CA 2461248 A CA2461248 A CA 2461248A CA 2461248 C CA2461248 C CA 2461248C
Authority
CA
Canada
Prior art keywords
receptor
compound
ht2a
compounds
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA 2461248
Other languages
English (en)
Other versions
CA2461248A1 (fr
Inventor
Erik Buntinx
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PharmaNeuroBoost NV
Original Assignee
PharmaNeuroBoost NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from CA2451798A external-priority patent/CA2451798C/fr
Application filed by PharmaNeuroBoost NV filed Critical PharmaNeuroBoost NV
Priority to CA 2461248 priority Critical patent/CA2461248C/fr
Priority to CA 2487529 priority patent/CA2487529A1/fr
Priority to RSP-2010/0323A priority patent/RS51331B/en
Priority to PL04801138T priority patent/PL1708790T3/pl
Priority to DE602004026781T priority patent/DE602004026781D1/de
Priority to EP04801138A priority patent/EP1708790B1/fr
Priority to DK04801138.1T priority patent/DK1708790T3/da
Priority to SI200431439T priority patent/SI1708790T1/sl
Priority to US10/580,962 priority patent/US8304431B2/en
Priority to AT04801138T priority patent/ATE464901T1/de
Priority to EP10159625A priority patent/EP2272514A1/fr
Priority to ES04801138T priority patent/ES2343962T3/es
Priority to PT04801138T priority patent/PT1708790E/pt
Priority to CA002547639A priority patent/CA2547639A1/fr
Priority to PCT/BE2004/000172 priority patent/WO2005053796A1/fr
Priority to JP2006541759A priority patent/JP4571645B2/ja
Publication of CA2461248A1 publication Critical patent/CA2461248A1/fr
Publication of CA2461248C publication Critical patent/CA2461248C/fr
Application granted granted Critical
Priority to CY20101100611T priority patent/CY1111017T1/el
Priority to HR20100376T priority patent/HRP20100376T1/hr
Priority to US12/924,615 priority patent/US20110136865A1/en
Priority to US13/065,638 priority patent/US20110207776A1/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Landscapes

  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA 2461248 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a Expired - Fee Related CA2461248C (fr)

Priority Applications (20)

Application Number Priority Date Filing Date Title
CA 2461248 CA2461248C (fr) 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
CA 2487529 CA2487529A1 (fr) 2003-12-02 2004-11-15 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
EP10159625A EP2272514A1 (fr) 2003-12-02 2004-12-02 Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
CA002547639A CA2547639A1 (fr) 2003-12-02 2004-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
DE602004026781T DE602004026781D1 (de) 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonist
EP04801138A EP1708790B1 (fr) 2003-12-02 2004-12-02 Utilisation de pipamperone et d'un antagoniste des recepteurs d2 ou d'un antagoniste a la dopamine et a la serotonine pour le traitement de troubles psychotiques
DK04801138.1T DK1708790T3 (da) 2003-12-02 2004-12-02 Anvendelse af pipamperon af en D2-receptorantagonist eller serotonin/dopaminantagonist til behandling af psykotiske sygdomme
SI200431439T SI1708790T1 (sl) 2003-12-02 2004-12-02 Uporaba pipamerona in d receptorskega antagonista kot serotonin dopamin antagonista za zdravljenjepsihičnih nepravilnosti
US10/580,962 US8304431B2 (en) 2003-12-02 2004-12-02 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
AT04801138T ATE464901T1 (de) 2003-12-02 2004-12-02 Verwendung von pipamperon und einem d2-rezeptor antagonisten oder einem serotonin/dopamin antagonisten zur behandlung von psychotischen störungen
RSP-2010/0323A RS51331B (en) 2003-12-02 2004-12-02 USE OF PIPAMPERON AND D2-RECEPTOR ANTAGONISTS OR SEROTONIN / DOPAMINE ANTAGONISTS FOR THE TREATMENT OF PSYCHOTIC DISORDERS
ES04801138T ES2343962T3 (es) 2003-12-02 2004-12-02 Uso de pipamperona y un antagonista de receptores d2 o un antagonista de serotonina/dopamina para el tratamiento de trastornos psicoticos.
PT04801138T PT1708790E (pt) 2003-12-02 2004-12-02 Utilizaã†o de pipamperona e de um antagonista dos receptores d2 ou de um antagonista da dopamina e da serotonina para o tratamento de transtornos psicëticos
PL04801138T PL1708790T3 (pl) 2003-12-02 2004-12-02 Zastosowanie pipamperonu oraz antagonisty receptora D2 lub antagonisty receptora serotoniny/dopaminy do leczenia zaburzeń psychotycznych
PCT/BE2004/000172 WO2005053796A1 (fr) 2003-12-02 2004-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels d4 et 5ht2a,
JP2006541759A JP4571645B2 (ja) 2003-12-02 2004-12-02 Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
CY20101100611T CY1111017T1 (el) 2003-12-02 2010-07-05 Χρηση πιπαμπερονης και ενος ανταγωνιστη d-2 υποδοχεα ή ανταγωνιστη σεροτονινης/ντοπαμινης για την θεραπεια ψυχωτικων διαταραχων
HR20100376T HRP20100376T1 (hr) 2003-12-02 2010-07-06 Uporaba pipamperona i antagonista d2-receptora ili antagonista serotonin/dopamina za liječenje psihotičnih poremećaja
US12/924,615 US20110136865A1 (en) 2003-12-02 2010-09-30 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US13/065,638 US20110207776A1 (en) 2003-12-02 2011-03-25 Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CA2451798A CA2451798C (fr) 2003-12-02 2003-12-02 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
CA2,451,798 2003-12-02
EP04447001.1 2004-01-05
EP04447001 2004-01-05
CA 2461248 CA2461248C (fr) 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a

Publications (2)

Publication Number Publication Date
CA2461248A1 CA2461248A1 (fr) 2005-06-02
CA2461248C true CA2461248C (fr) 2009-12-22

Family

ID=34623380

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2461248 Expired - Fee Related CA2461248C (fr) 2003-12-02 2004-03-18 Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a

Country Status (1)

Country Link
CA (1) CA2461248C (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2272514A1 (fr) 2003-12-02 2011-01-12 PharmaNeuroBoost N.V. Utilisation d'une faible dose de pipamperone et d'un deuxième agent actif dans le traitement des maladies neurodégénératives
US7855195B2 (en) 2003-12-02 2010-12-21 Pharmaneuroboost N.V. Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US7884096B2 (en) 2003-12-02 2011-02-08 Pharmaneuroboost N.V. Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
WO2021139874A1 (fr) * 2020-01-06 2021-07-15 Anima Prévention et traitement de troubles cognitifs

Also Published As

Publication number Publication date
CA2461248A1 (fr) 2005-06-02

Similar Documents

Publication Publication Date Title
US8304431B2 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050119249A1 (en) Method of treating neurodegenerative diseases using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20050203130A1 (en) Use of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
DE60200492T2 (de) Kombination eines Inhibitoren der Serotoninwiederaufnahme und eines atypischen Antipsychotikums zur Behandlung von Depression, Zwangsneurosen und Psychosen
US7855195B2 (en) Method of treating mental disorders using D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20110172251A1 (en) Method of treating mental disorders using of D4 and 5-HT2A antagonists, inverse agonists or partial agonists
US20060211686A1 (en) Alpha7 Neuronal nicotinic receptor ligand and antipsychotic compositions
US9732059B2 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
EA015566B1 (ru) Применение пептидного соединения для добавочной терапии к антагонисту дофамина и фармацевтическая композиция, его содержащая
JP4571485B2 (ja) Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
JP2023523569A (ja) 神経学的および精神障害の治療方法
EP1576985A1 (fr) Utilisation d'antagonistes, d'agonistes partiels ou d'agonistes inverses des recepturs D4 et 5-HT2A
US20220274951A1 (en) Methods of use of cyclic amide derivatives to treat schizophrenia
WO2006000222A2 (fr) Combinaison d'un antipsychotique et d'un inhibiteur de type 1 transporteur de glycine pour le traitement de la schizophrenie
CA2461248C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des recepteurs d4 et 5-ht2a
EP1547650A1 (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels des récepteurs D4 et 5-HT2A
US20120010242A1 (en) Low dose pipamperone in treating mood disorders
EP2236138A1 (fr) Pipampèrone faible dose pour le traitement des troubles de l`anxiété et de l`humeur
EP2236157A1 (fr) Pipampérone et un agent ultérieur pour le traitement des troubles de l'humeur et de l'anxiété
JP4571645B2 (ja) Ｄ４および５−ｈｔ２ａアンタゴニスト、逆アゴニストまたは部分アゴニストの使用
CA2451798C (fr) Utilisation d'antagonistes, d'agonistes inverses ou d'agonistes partiels de d4 et de 5-ht2a
WO2012072665A1 (fr) Compositions comprenant de la pipampérone et des antagonistes/inhibiteurs de la recapture de la sérotonine
AU2003263357A1 (en) Treatment of basal ganglia-related movement disorders with 2,3-benzodiazepines
JP2002524507A (ja) 新規組成物
PT1708790E (pt) Utilizaã†o de pipamperona e de um antagonista dos receptores d2 ou de um antagonista da dopamina e da serotonina para o tratamento de transtornos psicëticos

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20140318